{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:06:29Z","timestamp":1753891589863,"version":"3.41.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> It is thought that older patients with multiple sclerosis (MS) may present with a different clinical disease phenotype, and therefore respond to subcutaneous interferon beta-1a (sc IFN \u03b2-1a) differently to younger patients. However, few real-world data are available concerning the effectiveness of sc IFN \u03b2-1a according to age. Using data from US claims databases, this cohort analysis aimed to determine the differences in relapse rates, healthcare utilization, treatment adherence, and discontinuation according to pre-defined age groups.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Patient data were pooled from the IBM\u00ae MarketScan\u00ae Commercial Claims Database and Medicare Supplemental Database. Patients with a confirmed MS diagnosis who initiated treatment with sc IFN \u03b2-1a between July 01, 2010 and December 31, 2015, along with at least 6 months continuous enrolment in a healthcare plan, were followed from first prescription (index date) until date of discontinuation, treatment switch, or end of observation period (1 year after index date).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Of the 5,340 patients included in the analysis, there was a high proportion of patients free from relapse across all age groups (range: 94.1\u201395.4%), with a numerical decrease in the number of MRI performed by age (mean: 0.25, 18\u201330 years; 0.20, 31\u201340 years; 0.16, 41\u201350 years; 0.14, \u226551 years). Adherence (\u226580%) was seen to increase with age (77.6%, 18\u201330 years; 79.6%, 31\u201340 years; 81.3%, 41\u201350 years; 84.0%, \u226551 years), at the same time as a non-significant decrease in discontinuation (incidence rate: 79.91, 73.01, 71.75, 68.71%).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The effectiveness of sc IFN \u03b2-1a does not appear reduced as a consequence of age in this real-world setting. Older patients had lower discontinuation rates and reduced disease activity, reflected in lower relapse rates and fewer MRI scans compared with younger patients.<\/jats:p>","DOI":"10.3389\/fneur.2021.676585","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T07:38:49Z","timestamp":1626939529000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database"],"prefix":"10.3389","volume":"12","author":[{"given":"Arthur","family":"Allignol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Boutmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meritxell","family":"Sabid\u00f3 Espin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Marhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"B1","unstructured":"Atlas of MS, 3rd ed2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000360528","article-title":"Multiple sclerosis: current knowledge and future outlook","volume":"72","author":"Kamm","year":"2014","journal-title":"Eur Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/135245850100700110","article-title":"Disability and prognosis in multiple sclerosis: Demographic and clinical variables important for the ability to walk and awarding of disability pension","volume":"7","author":"Myhr","year":"2001","journal-title":"Mult Scler J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1212\/WNL.0b013e318230a17d","article-title":"Age and disability accumulation in multiple sclerosis","volume":"77","author":"Scalfari","year":"2011","journal-title":"Neurology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0165846","DOI":"10.1371\/journal.pone.0165846","article-title":"Is time to reach EDSS 6","volume":"11","author":"Alroughani","year":"2016","journal-title":"PLoS ONE."},{"key":"B7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/1352458516634871","article-title":"Aging and multiple sclerosis","volume":"22","author":"Sanai","year":"2016","journal-title":"Mult Scler J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"608491","DOI":"10.3389\/fneur.2021.608491","article-title":"Deciphering multiple sclerosis progression","volume":"12","author":"Meca-Lallana","year":"2021","journal-title":"Front Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","article-title":"Epidemiology and treatment of multiple sclerosis in elderly populations","volume":"15","author":"Vaughn","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B10","unstructured":"CascioneM\n            DangondF\n            FangJ\n            MillerA\n          Clinical and MRI Benefits of IFN Beta-1a 44 \u03bcg SC tiw Treatment Over 1 Year in Patients With RMS: Subgroup Analyses of the PRISMS Study2015"},{"key":"B11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12883-018-1145-x","article-title":"Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing\u2013remitting multiple sclerosis at year 1","volume":"18","author":"Traboulsee","year":"2018","journal-title":"BMC Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments","volume":"8","author":"Weideman","year":"2017","journal-title":"Front Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.msard.2017.11.022","article-title":"Validation of an algorithm to detect severe MS relapses in administrative health databases","volume":"19","author":"Marriott","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1185\/03007990903126833","article-title":"Good and poor adherence: optimal cut-point for adherence measures using administrative claims data","volume":"25","author":"Karve","year":"2009","journal-title":"Curr Med Res Opin."},{"key":"B15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000382130","article-title":"Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review","volume":"44","author":"Kalincik","year":"2015","journal-title":"Neuroepidemiology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1212\/WNL.0000000000001094","article-title":"Relapses and disability accumulation in progressive multiple sclerosis","volume":"84","author":"Paz","year":"2015","journal-title":"Neurology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11910-020-01046-2","article-title":"Impact of age on multiple sclerosis disease activity and progression","volume":"20","author":"Zeydan","year":"2020","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B18","unstructured":"MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of MS, 2018 Revised Guidelines2018"},{"key":"B19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00415-009-0096-y","article-title":"Factors that influence adherence with disease-modifying therapy in MS","volume":"256","author":"Treadaway","year":"2009","journal-title":"J Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1186\/s12913-020-05664-x","article-title":"Persistence, adherence, healthcare resource utilisation and costs for interferon beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)","volume":"20","author":"Moccia","year":"2020","journal-title":"BMC Health Serv Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12883-017-0831-4","article-title":"Reasons for discontinuation of subcutaneous interferon \u03b2-1a three times a week among patients with multiple sclerosis: a real-world cohort study","volume":"17","author":"Sabid\u00f3-Espin","year":"2017","journal-title":"BMC Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e35600","DOI":"10.1371\/journal.pone.0035600","article-title":"Adherence to interferon \u03b2-1b treatment in patients with multiple sclerosis in Spain","volume":"7","author":"Fern\u00e1ndez","year":"2012","journal-title":"PLoS ONE."},{"key":"B23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12883-020-01830-0","article-title":"Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"20","author":"Nicholas","year":"2020","journal-title":"BMC Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1756286420969016","DOI":"10.1177\/1756286420969016","article-title":"Aging and efficacy of disease-modifying therapies in multiple sclerosis: A meta-analysis of clinical trials","volume":"13","author":"Zhang","year":"2020","journal-title":"Ther Adv Neurol Diso."},{"key":"B25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.msard.2016.05.006","article-title":"Adherence and persistence to drug therapies for multiple sclerosis: a population-based study","volume":"8","author":"Evans","year":"2016","journal-title":"Mult Scler Relat Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0133279","DOI":"10.1371\/journal.pone.0133279","article-title":"Adherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort study","volume":"10","author":"Hansen","year":"2015","journal-title":"PLoS ONE."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0160313","DOI":"10.1371\/journal.pone.0160313","article-title":"Long-term adherence to IFN beta-1a treatment when using RebiSmart\u00ae device in patients with relapsing-remitting multiple sclerosis","volume":"11","author":"Fern\u00e1ndez","year":"2016","journal-title":"PLoS ONE."},{"key":"B28","unstructured":"Adherence to Long-Term Therapies - Evidence for Action2003"},{"key":"B29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B30","first-page":"P2","article-title":"Development of an algorithm to identify multiple sclerosis (MS) disease severity based on healthcare costs in a US administrative claims database (P2.052)","volume":"8","author":"Nicholas","year":"2017","journal-title":"Neurology."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.676585\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T14:41:04Z","timestamp":1627310464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.676585\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":30,"alternative-id":["10.3389\/fneur.2021.676585"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.676585","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2021,7,22]]},"article-number":"676585"}}